Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis

INTRODUCTION: Studies indicate similar survival and toxicity between pazopanib and sunitinib, but few have examined real-world outcomes among elderly patients with advanced renal cell carcinoma (RCC). The purpose of this retrospective claims analysis was to assess real-world overall survival (OS), h...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelzang, Nicholas J., Pal, Sumanta K., Ghate, Sameer R., Swallow, Elyse, Li, Nanxin, Peeples, Miranda, Zichlin, Miriam L., Meiselbach, Mark K., Perez, Jose Ricardo, Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702370/
https://www.ncbi.nlm.nih.gov/pubmed/29076108
http://dx.doi.org/10.1007/s12325-017-0628-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702370/
https://www.ncbi.nlm.nih.gov/pubmed/29076108
http://dx.doi.org/10.1007/s12325-017-0628-2

Ejemplares similares